Aponvie (aprepitant) — Medical Benefit Pharmaceutical Policy
Customize your policy alerts
Sign up for Geisinger Health Plan Policy MBP 299.0 alerts
Get alerted when Policy MBP 299.0 changes without checking for updates manually.
Monitor payer policy activity
This medical benefit pharmaceutical policy governs prior authorization and coverage criteria for Aponvie (aprepitant) for prevention of postoperative nausea and vomiting (PONV) for Geisinger Health Plan members across applicable commercial, Medicare, and CHIP lines of business.
No material clinical or coverage changes in this revision.
Coverage Criteria for Aponvie (aprepitant)
Initial authorization criteria
Aponvie (aprepitant) will be considered medically necessary when ALL of the following are met:
Eligibility and contract-specific benefit limitations and exclusions apply to coverage of Aponvie (aprepitant). Line of business benefit documents (for example, Commercial, Medicare, or CHIP plan benefit booklets) take precedence and will supersede the statements in this policy when there is a conflict.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.